Jacobs Levy Equity Management, Inc Pacira Bio Sciences, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 454,261 shares of PCRX stock, worth $11.6 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
454,261Holding current value
$11.6 Million% of portfolio
0.03%Shares
13 transactions
Others Institutions Holding PCRX
# of Institutions
259Shares Held
49.7MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$204 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$134 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$83 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$57.4 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$50.7 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.17B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...